Two new studies showed that people with “hybrid immunity”, that is, they received the full vaccine and were infected with Covid-19, have the greatest protection from the Corona virus.
These two studies shed light on the importance of vaccinations for those who have generated natural immunity after recovering from a corona infection they were exposed to.
The two studies, the results of which were published in the Lancet Infectious Diseases journal, stressed the importance of those recovering from the virus receiving corona vaccines.
One of the two studies analyzed the health data of more than 200,000 people in 2020 and 2021 in Brazil, which had the second highest death toll in the world.
And it was found that the infection provided people who had contracted Covid and received the “Pfizer” or “AstraZeneca” vaccine with 90 percent protection from hospitalization or death, compared to 81 percent for the Chinese “Koronavac” vaccine and 58 percent for the “Johnson & Johnson” vaccine that is taken. One dose.
“These four vaccines have proven to provide significant additional protection for those previously infected with Covid-19,” said study author Julio Costa, from the Federal University of Mato Grosso do Sul.
“Hybrid immunity induced by exposure to natural infection and vaccination will likely become the global standard, and may provide long-term protection against emerging mutants,” said Pramod Kumar of the Translational Health Science and Technology Institute in India.
A study based on Sweden’s national records up to October 2021 concluded that people who have recovered from Covid maintain a high level of protection from a new infection, up to about 20 months.
And it showed that for people who received two doses of the vaccine with hybrid immunity, the risk of infection again decreased by 66 percent compared to people who had only natural immunity.
Paul Hunter, a professor of medicine at the University of East Anglia who was not involved in the study, told AFP that 20 months of “very good protection is much better than what we would expect from a two-dose vaccine programme.”
But he cautioned that the two studies were completed before the “Omicron” mutant became dominant in the world, noting that “it led to a significant decrease in the protection provided by a previous infection.”
The results of a study, recently published on the medical website medRxiv, revealed the protection provided by “hybrid” immunity against “Omicron” and found that 3 doses were effective by 52 percent of the “Omicron” sub-mutant “BA2”, and the effectiveness rate increased to 77 percent. In the event of a previous injury.
The study, which was not reviewed, found that “hybrid immunity from previous infection and enhanced vaccination confers the strongest protection” against the original omicron mutant and its sub-strain.